Humacyte rises on Department of Defense funding for lab-made blood vessels

Humacyte

09/02/2026 20:03

** Shares of biotech co Humacyte HUMA.O rise 28.4% to $1.21

** Co says new Department of Defense funding supports procurement of bioengineered blood vessels

** Co's Symvess is the only human-derived bioengineered blood vessel approved by the US FDA

** Symvess is a lab blood vessel indicated for use in adults to fix arterial injuries in the limbs

** "We are grateful to Congress for directing targeted federal resources for the Department of Defense to acquire biologic vascular repair technology that can be used in combat to treat and repair traumatic vascular injuries in military personnel" — HUMA

** Stock had fallen 81% in 2025

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))